Glen Eagle Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Glen Eagle Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.96K	Hold	36	–	–	﹤0.01%	897
2026 Q1	$1.71K	Buy	+36	New	+$1.9K	﹤0.01%	866
2021 Q4	–	Sell	-180	Closed	-$20.1K	–	970
2021 Q3	$20.1K	Hold	180	–	–	0.01%	557
2021 Q2	$29.1K	Hold	180	–	–	0.01%	475
2021 Q1	$21.9K	Hold	180	–	–	0.01%	505
2020 Q4	$27.6K	Hold	180	–	–	0.01%	434
2020 Q3	$15.1K	Hold	180	–	–	0.01%	514
2020 Q2	$13.2K	Hold	180	–	–	0.01%	514
2020 Q1	$7.63K	Buy	180 +70	+64%	+$3.61K	0.01%	560
2019 Q4	$6.7K	Buy	+110	New	+$6.01K	﹤0.01%	667

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Glen Eagle Advisors's CRSP Position: Q2 2026 in Review

Glen Eagle Advisors held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 36 shares worth $1.96K. The position accounts for ﹤0.01% of the portfolio, ranked #897.

Glen Eagle Advisors first reported a position in CRSP in Q4 2019 and has held it in 10 quarters since. The position peaked at $29.1K in Q2 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Glen Eagle Advisors held 36 shares of CRISPR Therapeutics worth $1.96K as of Q2 2026.
Glen Eagle Advisors left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Glen Eagle Advisors's portfolio in Q2 2026, its #897 holding.
Glen Eagle Advisors first reported a position in CRISPR Therapeutics in Q4 2019 and has held it in 10 quarters since.
Glen Eagle Advisors's CRISPR Therapeutics position peaked at $29.1K in Q2 2021.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Glen Eagle Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.